Aix-Marseille Univ

Oct 27, 2024 | bmcpulmmed.biomedcentral.com | Aix Marseille Univ |Aix-Marseille Univ

We conducted a retrospective monocentric study in the department of respiratory medicine of hospital Nord in Marseille, France between January 2010 and February 2024. In our hospital, SSc-ILD patients treated with MMF are monitored by RR in routine clinical practice. To be eligible, patients had to fulfill ACR/EULAR criteria [26] for SSc with ILD assessed by an expert radiologist in Multidisciplinary Discussion (MDD), to receive MMF (Cellcept® or Myfortic®) and to have a measurement of MPA-RR.

Jul 29, 2024 | bmccancer.biomedcentral.com | Institut Gustave Roussy |Aix-Marseille Univ |Institut Paoli-Calmettes |Institut Català d’Oncologia

Alejandro Pérez-Fidalgo and Ana Oaknin contributed equally to this work.

Jul 21, 2024 | bmccancer.biomedcentral.com | Institut Gustave Roussy |Aix-Marseille Univ |Institut Paoli-Calmettes |Institut Català d’Oncologia

ENDOLUNG was an open-label phase 1/2 study of the combination of ABTL0812 plus CP in advanced or recurrent EC patients (the phase 1 also included patients with sq-NSCLC). Patients were recruited in 9 academic institutions, located in Spain and France, from November 2016 to February 2020. This study was registered with EudraCT number 2016-001352-21 and at ClinicalTrials.gov with identifier NCT03366480. During the phase 1, patients were recruited only in 6 academic institutions from Spain.

Apr 15, 2024 | ijbnpa.biomedcentral.com | Aix-Marseille Univ |Université de Toulon

The study design consisted of three conditions into which participants were randomly assigned: exposure to advertising messages with the Nutri-Score displayed vs. exposure to advertising messages without the Nutri-Score vs. no exposure to advertising messages (control condition) (Fig. 1). The independent variable was called the “messages with vs. without the Nutri-Score” variable. Examples of advertising messages and products used in experimental and control conditions.

Sep 8, 2023 | frontiersin.org | Clinical Bioinformatics |Bioinformatics Unit |Van Helden |Aix-Marseille Univ

Introduction High-throughput Sequencing (HTS) has made a huge impact in medicine, and pushed us into the era of personalized and genomic medicine. Microbiology is one of the fields where an unprecedented revolution has taken place, as HTS allows genomic characterization of pathogens of interest at clinical and public health levels, which eases their surveillance and outbreak control, making the concept of One Health (1, 2) a reality.